74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
ANI Pharmaceuticals Inc
Open
SectorHealthcare
67.56 -1.43
Overview
Share price change
24h
Min
66.04
Max
69.37
Income | 12M -10M |
|---|---|
Sales | 42M 191M |
P/E Sector Avg | 50.13 63.778 |
EPS | -0.55 |
Profit margin | -5.392 |
Employees | 897 |
EBITDA | 28M 15M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +24.96% upside |
Next Earnings | 9 May 2025 |
|---|
Market Cap | 248M 1.5B |
|---|---|
Previous open | 68.99 |
Previous close | 67.56 |
News Sentiment
By Acuity
93%
7%
372 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
ANI Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
ANI Pharmaceuticals Inc Forecast
Price Target
By TipRanks
24.96% upside
12 Months Forecast
Average 85 USD 24.96%
High 94 USD
Low 80 USD
Based on 7 Wall Street analysts offering 12 month price targets forANI Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
372 / 386 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
